Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.70 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.41 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.40 |
| ▸ | PRKACA | P17612 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.39 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.38 |
| ▸ | XDH | P47989 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29392628 | 1.00 | CYP1A2 (0.70) | CYP1A2CYP3A4CYP2D6CYP2C19HTT | |
| SCHEMBL7561776 | 0.87 | CYP1A2 (0.57) | CYP1A2CYP3A4CYP2D6CYP2C19HTT | |
| SCHEMBL16146620 | 0.82 | CYP1A2 (0.47) | CYP1A2CYP3A4CYP2D6CYP2C19HTT | |
| SCHEMBL16145767 | 0.81 | CYP3A4 (0.46) | CYP1A2CYP3A4CYP2D6CYP2C19HTT | |
| SCHEMBL16146190 | 0.81 | NUDT1 (0.61) | CYP1A2CYP3A4CYP2D6CYP2C19NUDT1 | |
| SCHEMBL20117 | 0.80 | CYP1A2 (0.45) | CYP1A2CYP3A4CYP2D6CYP2C19HTT | |
| SCHEMBL101669 | 0.80 | CYP3A4 (0.67) | CYP1A2CYP3A4CYP2D6CYP2C19HTT | |
| SCHEMBL29404312 | 0.80 | CYP3A4 (0.67) | CYP1A2CYP3A4CYP2D6CYP2C19HTT | |
| SCHEMBL31012324 | 0.77 | CYP2C19 (0.63) | CYP1A2CYP3A4CYP2D6CYP2C19HTT | |
| SCHEMBL17372399 | 0.77 | CYP2C19 (0.63) | CYP1A2CYP3A4CYP2D6CYP2C19HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 508 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2694524-B1 | 2'-O-AMINOOXYMETHYL NUCLEOSIDE DERIVATIVES FOR USE IN THE SYNTHESIS AND MODIFICATION OF NUCLEOSIDES, NUCLEOTIDES AND OLIGONUCLEOTIDES | US HEALTH (US) | 2016-05-18 | — | — | EP | claimed |
| US-9284343-B2 | 2′-O-aminooxymethyl nucleoside derivatives for use in the synthesis and modification of nucleosides, nucleotides and oligonucleotides | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-03-15 | — | — | US | claimed |
| EP-2567964-B1 | Monomer compositions for the synthesis of RNA, methods of synthesis, and methods of deprotection | AGILENT TECHNOLOGIES INC (US) | 2015-02-11 | — | — | EP | claimed |
| US-20140051846-A1 | 2'-O-AMINOOXYMETHYL NUCLEOSIDE DERIVATIVES FOR USE IN THE SYNTHESIS AND MODIFICATION OF NUCLEOSIDES, NUCLEOTIDES AND OLIGONUCLEOTIDES | TheUnited ofAmerica,asrepresentedbythe Secre -tary,Department ofHealthand Human Service (US) | 2014-02-20 | — | — | US | claimed |
| EP-2694524-A1 | 2'-O-AMINOOXYMETHYL NUCLEOSIDE DERIVATIVES FOR USE IN THE SYNTHESIS AND MODIFICATION OF NUCLEOSIDES, NUCLEOTIDES AND OLIGONUCLEOTIDES | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) | 2014-02-12 | — | — | EP | claimed |
| WO-2012138530-A1 | 2'-O-AMINOOXYMETHYL NUCLEOSIDE DERIVATIVES FOR USE IN THE SYNTHESIS AND MODIFICATION OF NUCLEOSIDES, NUCLEOTIDES AND OLIGONUCLEOTIDES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-10-11 | — | — | WO | claimed |
| US-7807356-B2 | Labeled nucleotide composition | AGILENT TECHNOLOGIES, INC. (US) | 2010-10-05 | — | — | US | claimed |
| US-7524942-B2 | Labeled nucleotide composition | AGILENT TECHNOLOGIES, INC. (US) | 2009-04-28 | — | — | US | claimed |
| US-20080124708-A1 | Labeled nucleotide composition | AGILENT TECHNOLOGIES, INC. | 2008-05-29 | — | — | US | claimed |
| US-20070212697-A1 | Labeled nucleotide composition | AGILENT TECHNOLOGIES, INC. | 2007-09-13 | — | — | US | claimed |
| EP-4748940-A2 | DE NOVO SYNTHESISED GENE LIBRARIES | Twist Bioscience Corporation (US) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026106497-A2 | FUNCTIONALIZED CIRCULAR RNA AND METHODS AND INTERMEDIATES FOR THEIR PRODUCTION | SIEĆ BADAWCZA ŁUKASIEWICZ – PORT POLSKI OSRODEK ROZWOJU TECHNOLOGII (PL) | 2026-05-21 | — | — | WO | disclosed |
| US-20260138111-A1 | DE NOVO SYNTHESIZED GENE LIBRARIES | Twist Bioscience Corporation (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4743580-A1 | EFFICIENT TRANSGENE-FREE GENOME EDITING IN PLANTS IN THE T0 GENERATION BASED ON A CO-EDITING STRATEGY | University of Florida Research Foundation, Incorporated (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-3790985-B1 | METHODS OF SYNTHESIZING A POLYNUCLEOTIDE ARRAY USING PHOTACTIVATED AGENTS | VIBRANT HOLDINGS LLC (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-1105404-A1 | PURIFICATION OF OLIGOMERS USING DUAL-END SELECTION | Bayer Corporation (US) | 2001-06-13 | — | — | EP | disclosed |
| US-6222030-B1 | CONDENSING HYDROXY GROUP OF BOUND OLIGONUCLEOTIDE OR NUCLEOSIDE WITH NUCLEOSIDE PHOSPHORAMIDITE HAVING CARBONATE-PROTECTED HYDROXYL GROUP, TREATING WITH DEPROTECTING AGENT ALSO OXIDIZES PHOSPHITE TRIESTER LINKAGE | AGILENT TECHNOLOGIES, INC. | 2001-04-24 | — | — | US | disclosed |
| WO-2001014401-A1 | NUCLEOSIDE PYROPHOSPHATE AND TRIPHOSPHATE ANALOGS AND RELATED COMPOUNDS AS THERAPEUTIC AGENTS | SRI INTERNATIONAL (US) | 2001-03-01 | — | — | WO | disclosed |
| WO-2000012524-A1 | PURIFICATION OF OLIGOMERS USING DUAL-END SELECTION | BAYER CORPORATION (US) | 2000-03-09 | — | — | WO | disclosed |
| EP-0984021-A2 | Synthesis of oligonucleotides | Hewlett-Packard Company (US) | 2000-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080124708-A1 | Labeled nucleotide composition | RNGTT, RNMT, NOP2 | CYP1A2 3227/4885CYP3A4 3828/4885CYP2D6 2787/4885 |
| US-20070212697-A1 | Labeled nucleotide composition | RNGTT, RNMT, NOP2 | CYP1A2 3227/4885CYP3A4 3828/4885CYP2D6 2787/4885 |
| US-20260138111-A1 | DE NOVO SYNTHESIZED GENE LIBRARIES | POLM, DNMT3A, POLN | CYP1A2 2361/4885CYP3A4 2960/4885CYP2D6 1210/4885 |
| US-20140051846-A1 | 2'-O-AMINOOXYMETHYL NUCLEOSIDE DERIVATIVES FOR USE IN THE SYNTHESIS AND MODIFICATION OF NUCLEOSIDES, NUCLEOTIDES AND OLIGONUCLEOTIDES | NSUN2, RNGTT, RNMT | CYP1A2 3150/4885CYP3A4 3895/4885CYP2D6 2529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.